怀孕期间霍奇金淋巴瘤的管理，对与良好结果相关的同质期望态度的文献综述和描述
Management of Hodgkin Lymphoma during pregnancy, review of the literature and description of an homogenous expectative attitude associated with excellent outcome
影响因子:5.60000
分区:医学2区 Top / 血液学2区 肿瘤学2区
发表日期:2024 Nov
作者:
Joshua Hagège, Lorea Aguinaga, Hannah Moatti, Roberta Di Blasi, Catherine Thieblemont, Pauline Brice, Loïc Renaud
摘要
怀孕期间出现的霍奇金淋巴瘤（HL）是一种罕见的疾病，管理依赖于稀疏文献。怀孕的特异性要求临床医生考虑临床紧急情况，淋巴瘤的阶段，妊娠期和患者的选择。主要目标是双重的：限制母亲和胎儿的毒性和不良事件的风险，而不会减少成功结果的机会。当前的文献数据表明，使用ABVD型多化学疗法（Adriamcin，Bleymycin，Vinblastine，dacarbazine）与产科事件和长期胎儿毒性有关。我们在这里报告了考虑等待观察，文蓝色单一疗法和ABVD多化化学疗法选择的同质管理结果。在产科并发症，反应率和总体生存率（100％）方面的结果加强了这样一种观念，即不涉及使用多药治疗的策略是可能的，并且与非常好的结果相关。
Abstract
Hodgkin lymphoma (HL) occuring during pregnancy is a rare condition, and management relies on sparse literature. The specificity of pregnancy requires the clinician to take into account the clinical emergency, the stage of the lymphoma, the trimester of pregnancy, and the patient's choices. The main objective is twofold: to limit the risk of toxicity and adverse events for both mother and fetus, without reducing the chances of a successful outcome. Current literature data suggest that the use of ABVD-type polychemotherapy (adriamycin, bleomycin, vinblastine, dacarbazine) is associated with obstetrical events and long-term fetal toxicity. We report here the results of a homogeneous management considering wait-and-see, vinblastine monotherapy and ABVD polychemotherapy options. The outcomes in terms of obstetrical complications, response rate, and overall survival (100 %) reinforce the idea that strategies that do not involve the use of multidrug therapy are possible and are associated with very good results.